MedTrace Logo

Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands

NCT01910831 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-12-02

Study results available
· View outcomes & findings →

Summary

To determine the efficacy (measured at 12 weeks) of DerMend Moisturizing Bruise Formula in improving the appearance of bruising and reducing the appearance of photoaging of the forearms and hands in mature skin. Assessments will be made through ongoing objective measurements and clinical ratings.

To confirm the safety (local tolerance) of DerMend Moisturizing Bruise Formula.

Conditions

  • Purpura

Interventions

DRUG

DerMend Moisturizing Bruise Formula

DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.

DRUG

Non-active placebo control

Non-active placebo control

Sponsors & Collaborators

  • Ferndale Laboratories, Inc.

    collaborator INDUSTRY

  • The Center for Clinical and Cosmetic Research

    lead OTHER

Principal Investigators

  • Mark S Nestor, MD, PhD · Director

  • Brian Berman, MD, PhD · Co-director

  • Julie A Santos, PA-C, CRC · Study Coordinator

  • Andrew C Frisina, MS · Study Coordinator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01910831 on ClinicalTrials.gov